Launch Therapeutics Selects Medidata AI Intelligent Trials

Medidata has announced that Launch Therapeutics (Launch Tx) selected Medidata AI Intelligent Trials to support its approach to accelerating clinical trials of late-stage therapies.

Medidata AI Intelligent Trials’ Study Feasibility solution provides Launch Tx with higher assurance that trial planning will improve enrollment and quality. This is done by leveraging country and site-level performance data, and predictive analytics. It’s built on a foundation of data from more than 30,000 clinical trials across a wide array of disease indications representing more than nine million study participants.

Reference

Launch Therapeutics Selects Medidata AI Intelligent Trials to Accelerate Clinical Trial Development. (2023, April 12). Medidata.